skip to content
Primary navigation


DrugSinuva™ (mometasone furoate implant) [Intersect ENT, Inc.]

April 2019

Therapeutic Area - Nasal polyps

Approval criteria

  • Patients is ≥ 18 years of age AND
  • Patient has a diagnosis of recurrent nasal polyps and chronic sinusitis (e.g., nasal obstruction/congestion, post-nasal discharge, thick nasal discharge, facial pain/pressure, or decreased sense of smell) and recurrent bilateral sinus obstruction AND
  • Patient has nasal obstruction/congestion score of ≥ 2 despite use of two preferred intranasal corticosteroids AND
  • Patient has undergone ethmoid sinus surgery > 90 days prior to implantation AND
  • Patient does not have a known hypersensitivity to mometasone furoate or any ingredient of the Sinuva sinus implant AND
  • Physician attests that he or she has specialized training in otolaryngology

Quantity limits

  • 1 implant for 90 days; no renewal

Billing for Sinuva

Sinuva must be billed as a medical claim.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top